Breaking News:

Abivax receives clearance from U.S. FDA to initiate clinical trials with ABX464 to treat moderate to severe ulcerative colitis.

For more information, you can find our press release under the following link: https://abivax.gcs-web.com/news-releases/news-release-details/abivax-receives-clearance-us-fda-initiate-clinical-trials-abx464

Share Profile

Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.

  • ISIN code: FR0012333284
  • Symbol: ABVX
  • ICB Classification: Healthcare 4000/ Biotechnology 4573
  • Market: Euronext Paris-Compartment C
  • Type of Listing: continuous
  • Number of outstanding shares: 11 808 939 as of 30 September 2019
  • Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
  • Eligible to French PEA PME

Analysts

LifeSci Capital Alpha Series:

Adam Evertts & David Sherman

Bryan, Garnier & Co:

Eric Le Berrigaud & Jean-Jacques Le Fur

goetzpartners securities:

Chris Redhead

Degroof Petercam:

Benoit Louage

NIBC:

Dylan van Haaften & Anita Ye

Kepler Cheuvreux:

Damien Choplain

Portzamparc:

Christophe Dombu

Investor Contact

Chris Maggos LifeSci Advisors Chris@lifesciadvisors.com +41 79 367 6254